The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease
- 1 June 2006
- Vol. 24 (23) , 5027-5035
- https://doi.org/10.1016/j.vaccine.2006.03.064
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Respiratory syncytial virus and other pneumoviruses: a review of the international symposium—RSV 2003Virus Research, 2004
- Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitisThe Lancet, 2004
- The Cotton Rat: An Underutilized Animal Model for Human Infectious Diseases Can Now Be Exploited Using Specific Reagents to Cytokines, Chemokines, and InterferonsJournal of Interferon & Cytokine Research, 2004
- Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virusVaccine, 2003
- Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid AInfection and Immunity, 2003
- Mechanisms of Monophosphoryl Lipid A Augmentation of Host Responses to Recombinant HagB fromPorphyromonas gingivalisInfection and Immunity, 2002
- Cytokine and Chemokine Gene Expression after Primary and Secondary Respiratory Syncytial Virus Infection in Cotton RatsThe Journal of Infectious Diseases, 2002
- Bronchiolitis‐Associated Mortality and Estimates of Respiratory Syncytial Virus–Associated Deaths among US Children, 1979–1997The Journal of Infectious Diseases, 2001
- Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulinVaccine, 1996
- Immune Response to Experimentally Induced Infection with Respiratory Syncytial Virus: Possible Role in the Development of Pulmonary DiseaseJournal of General Virology, 1989